SCHEMBL7375255

SCHEMBL7375255

Cc1cc(C)cc([C@@H](CO)C(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 5/20 0.43
AKR1C2 P52895 5/20 0.43
TPMT P51580 1/20 0.41
CPN1 P15169 1/20 0.36
CPB2 Q96IY4 1/20 0.36
PTGS2 P35354 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
AKR1C1 Q04828 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6374729 1.00 AKR1C3 (0.43) AKR1C3AKR1C2TPMTCPN1CPB2
SCHEMBL6374731 1.00 AKR1C3 (0.43) AKR1C3AKR1C2TPMTCPN1CPB2
SCHEMBL6367023 0.89 POLB (0.42) AKR1C3AKR1C2PTGS2SMN1; SMN2POLB
SCHEMBL6367015 0.89 POLB (0.42) AKR1C3AKR1C2PTGS2SMN1; SMN2POLB
SCHEMBL6367016 0.89 POLB (0.42) AKR1C3AKR1C2PTGS2SMN1; SMN2POLB
SCHEMBL6366399 0.84 AKR1C3 (0.43) AKR1C3AKR1C2PTGS2KDM4EAKR1C1
SCHEMBL564831 0.83 AKR1C3 (0.58) AKR1C3AKR1C2TPMTHTTNPSR1
SCHEMBL28322377 0.82 AKR1C3 (0.42) AKR1C3AKR1C2TPMTCPN1CPB2
SCHEMBL6366873 0.81 ACP3 (0.47) CPN1CPB2SMN1; SMN2TDP1PSEN1
SCHEMBL6366878 0.81 ACP3 (0.47) CPN1CPB2SMN1; SMN2TDP1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-14 US disclosed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US disclosed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP disclosed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors F2, SERPINC1, FGB AKR1C3 3984/4885AKR1C2 4246/4885TPMT 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.